An underground market for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.
Experimental Treatment Acquiring Traction Via Social Media
Retatrutide, which is still in research studies, is being promoted by social media influencers for its supposed weight-reducing effects. Followers are encouraged to contact these accounts directly for source information, while also receiving discount codes.
Thriving Trade on Messaging Platforms
Additionally, a flourishing trade exists on messaging services, where communities with thousands of members share comparison images, administration instructions and claims of next-day British shipping. Vendors promote the substance there before redirecting buyers to other platforms for transactions.
Learning About The Experimental Drug
This medication is an experimental injectable developed by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help patients reduce up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being promoted digitally as the successor to Ozempic.
Healthcare Experts Express Concerns
However, doctors and chemists have warned that the distribution of what is still an unapproved medication in the UK is a cause for concern and could lead to users injecting products of unknown origin.
Several professionals stated the demand for retatrutide could be linked to the increasing cost of approved slimming products such as Mounjaro.
Legal Status and Implementation
Marketing retatrutide on social media or messaging apps is prohibited in the UK, as it is an unapproved medication that must not be marketed or distributed for human use under the Human Medicines Regulations 2012.
Some content creators try to circumvent the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and supply can still breach pharmaceutical, marketing, and customer laws, risking penalties, legal action or prison.
Platform Reaction and Content Removal
Based on TikTok, the platform has removed problematic material and banned associated hashtags and query recommendations. The organization stated it was dedicated to keeping the service secure and investing in enhancing enforcement strategies.
Digital Trading Operations
Investigations also found groups with up to 9,000 members marketing retatrutide using Telegram's built-in search feature, which operates like a online catalog. Typing “retatrutide” instantly displays channels with thousands of members, populated with images of weight loss, positive reviews and detailed instructions for preparing or administering at residence.
After minutes of entering one community, a seller shared WhatsApp details, where the majority of purchases occur. The vendor provided an instruction manual and promised delivery within two days. When questioned whether the product was genuine, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one inquired about body mass, medical conditions or past usage.
Product Information and Costs
Within these communities, posts display black plastic parcels with postal service stickers, stating to include fresh supplies. One message stated: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, mixed at residence with purified liquid, or pre-filled injectors typically sold at 160 pounds for 20mg. When questioned how long a injector should be used, vendors give conflicting responses varying between a few weeks to “depends on your body”.
Platform Oversight and Security Measures
A representative for the messaging service stated it actively monitored harmful material on its platform including content that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Warnings
“Individuals are injecting substances they cannot confirm. Even if the science behind this drug is valid, these digital versions may not contain what they claim,” stated Jason Murphy, the head of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of an online medical service connected the surge in interest to recent cost increases for approved weight-loss medications such as Mounjaro. “With costs rising, patients are turning to social media. But fake injections are extremely dangerous. You can’t be certain what’s inside or whether the conditions they were made in was sterile,” she said.
Her team has already encountered patients harmed by self-injection from unconfirmed sources. “We recognize the frustration, but purchasing from Telegram or WhatsApp is taking chances with your well-being,” said Wyllie. “These materials could be contaminated or improperly measured.”
Producer Statement
A spokesperson from Eli Lilly said the substance was in phase 3 research studies and had not been evaluated or approved by any regulatory agency anywhere in the world. “Consequently at this point no one can sell [it] for personal consumption,” they explained, adding that any item “misleadingly claiming itself as a Lilly experimental substance not yet authorized … may expose users to possibly significant medical dangers”.
